Aardvark Therapeutics AARD
NASDAQ AARD
$4.99 -0.28 (-5.31%)
At close: Oct 2, 2026 · 4:00 PM EDT

Aardvark Therapeutics (AARD) Return on Equity [ROE] (2025 - 2026)

Updated

Aardvark Therapeutics (AARD) recorded Return on Equity [ROE] of -86.41% in Q2 2026, down 61.04 percentage points from -25.37% a year earlier and down 14.24 percentage points from the prior quarter.

Analysis

Aardvark Therapeutics (AARD) Return on Equity [ROE] (2025 - 2026) Analysis & Trends

For FY2025, Aardvark Therapeutics reported Return on Equity [ROE] of -221.53%.

  • Per Business Quant, the preceding three quarters came in at -72.17% (Q1 2026), -50.29% (Q4 2025) and -37.59% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 25.32%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 7.21%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 84.40%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 21.39%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 83.75%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -18.38%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 4.97%
10 Aardvark Therapeutics 109.20 Mn 35.30 Mn - -86.41%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -86.41%
Mar 31, 2026 -72.17%
Dec 31, 2025 -50.29%
Sep 30, 2025 -37.59%
Jun 30, 2025 -25.37%
Mar 31, 2025 -57.47%
API Access

Aardvark Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=AARD&period=max&api_key=YOUR_API_KEY